Nystatin · NYSTATIN 100000 U/mL · Suspension · Oral · Chartwell RX, LLC
NDC 62135-0813-46 · 60 mL in 1 BOTTLE · NDA AUTHORIZED GENERIC · View full market →
17 companies supply this market — deep enough that no single failure threatens the supply. The price has held steady around $0.1401 per mL over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
OAI inspection at a producing facility (24 months) · sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 3, 2026 |
| Pharmaceutical Associates, Inc. | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 3, 2026 |
| American Health Packaging | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | NYSTATIN 100000 U/mL | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell Governmental & Specialty RX, LLC | NYSTATIN 100000 U/mL | Jul 15, 2026 | Sep 2, 2026 |
| Chartwell RX, LLC | NYSTATIN 100000 U/mL | Jul 15, 2026 | Sep 2, 2026 |
| Genus Lifesciences Inc. | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| Kanchan Healthcare Inc | NYSTATIN 100000 U/mL | Jul 15, 2026 | Sep 2, 2026 |
| Leading Pharma, LLC | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| Major Pharmaceuticals | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| NuCare Pharmaceuticals,Inc. | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| Preferred Pharmaceuticals Inc. | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| Xttrium Laboratories, Inc. | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Sep 2, 2026 |
| Cardinal Health 107, LLC | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Aug 31, 2026 |
| PAI Holdings, LLC dba PAI Pharma | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Aug 31, 2026 |
| Atlantic Biologicals Corp. | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Aug 29, 2026 |
| Kesin Pharma Corporation | NYSTATIN 100000 U/mL | Jul 15, 2026 | Aug 28, 2026 |
| Taro Pharmaceuticals U.S.A., Inc. | NYSTATIN 100000 [USP'U]/mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Nystatin — NDC 62135-0813-46," retrieved September 3, 2026, https://drugdashboards.com/drug/62135081346.
Free to cite with attribution — see how the data is put together.